Tencent Technology (Shenzhen) Co. Ltd. has synthesized lysine-specific histone demethylase 1A (KDM1A; LSD1) inhibitors reported to be useful for the treatment of cancer.
Ventus Therapeutics US Inc. has divulged pyrido-[3,4-d]pyridazine amine derivatives acting as NLRP3 inflammasome inhibitors reported to be useful for the treatment of cancer, metabolic, autoimmune disease, liver, renal, respiratory, cardiovascular and inflammatory disorders, among others.
Alexion Pharmaceuticals Inc. has identified complement C1s subcomponent inhibitors reported to be useful for the treatment of immune thrombocytopenia purpura, lupus nephritis, amyotrophic lateral sclerosis, Guillain Barré syndrome, Huntington’s disease, rheumatoid arthritis, traumatic brain injury, and autoimmune hemolytic anemia, among others.
The University of Minnesota has disclosed monocarboxylate transporter (MCT1) inhibitors reported to be useful for the treatment of cancer, graft-vs.-host disease, nonalcoholic steatohepatitis, obesity and diabetes.
Ideaya Biosciences Inc. has described piperazine substituted indazole compounds acting as poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of cancer.
Autotelic Bio Inc. has divulged thiazole derivatives acting as TGF-β receptor type-1 (TGFBR1; ALK5; SKR4; TβR-I) inhibitors reported to be useful for the treatment of cancer.
A team at 1st Bio Therapeutics Inc. has identified indazoles acting as mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer, autoimmune disease and inflammatory disorders.
RSS